Last month, EBD and IMS partnered to analyze meeting outcomes from four conferences, covering nearly 5,000 participating companies. Their report is available here (PDF). As we are knee-deep in scheduling…
Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike's perspective is unique in that he has managed to…
The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data…
This question came up recently when I was describing one of our current clients as a "good" client. But what exactly is a "good" client? Three things come to…
What follows is a true story. In 2013, we were engaged to out-license a series of Preclinical assets. One of these assets was in a therapeutic area which had very few…
We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward…
Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress. The discussion was quite interesting, and we encourage…
We've started preparing for the BIO convention in Philadelphia in June. Preparing? Already? Yes. Why start now? We'll give you three reasons: New Partnering Interface - BIO has unveiled a…
From a consulting perspective, here is how we view business development, using the acronym LUNCH: Learn what the client wants: What is the objective? Is it cash now in the…
Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by…